首页> 外文期刊>Modern Pathology >Absence of expression of SMARCB1|[sol]|INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis
【24h】

Absence of expression of SMARCB1|[sol]|INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis

机译:中枢神经系统,肾脏和软组织恶性横纹肌瘤中SMARCB1 | [sol] | INI1表达的缺乏:免疫组化研究对诊断的意义

获取原文
           

摘要

Malignant rhabdoid tumors are high-grade neoplasms of the central nervous system (CNS), kidneys and soft tissue that usually occur in children. The histologic diagnosis of malignant rhabdoid tumor depends on identification of characteristic rhabdoid cells—large cells with eccentrically located nuclei and abundant, eosinophilic cytoplasm—and immunohistochemistry with antibodies to vimentin, keratin and epithelial membrane antigen. In most malignant rhabdoid tumors, the SMARCB1/INI1 gene, located in chromosome band 22q11.2, is inactivated by deletions and/or mutations, so genetic diagnosis is often possible. However, tissue may not be available for genetic analysis or studies not confirmatory. We assessed SMARCB1/INI1 expression in 17 rhabdoid tumors and 57 other tumors of the CNS, kidney or soft tissue using immunohistochemistry. In total, 12 brain, three renal and two soft tissue rhabdoid tumors were examined along with four glioblastomas, four pilocytic astrocytomas, four oligodendrogliomas, two ependymomas, two choroid plexus papillomas, five pituitary adenomas, four germinomas, four renal carcinomas with Xp11.2 translocations, two clear cell sarcomas, two Wilms' tumors, one renal medullary carcinoma, two desmoplastic small round cell tumors, two alveolar rhabdomyosarcomas, two embryonal rhabdomyosarcomas, one low-grade chondrosarcoma, two extraskeletal myxoid chondrosarcomas, one mesenchymal chondrosarcoma, four malignant peripheral nerve sheath tumors, five metastatic carcinomas and four epithelioid sarcomas, two primary and two metastatic. The neoplastic cells of all rhabdoid tumors, the four epithelioid sarcomas and the renal medullary carcinoma did not express SMARCB1/INI1 by immunohistochemistry; neoplastic cells of all other tumors expressed SMARCB1/INI1. Immunohistochemistry to assess expression of SMARCB1/INI1 may be useful in the diagnosis of rhabdoid tumors of the CNS, kidneys and soft tissue.
机译:恶性横纹肌瘤是儿童中常见的中枢神经系统(CNS),肾脏和软组织的高级肿瘤。恶性横纹肌瘤的组织学诊断取决于对特征性横纹肌细胞(具有偏心定位的核和大量嗜酸性粒细胞胞浆的大细胞)的鉴定,以及对波形蛋白,角蛋白和上皮膜抗原抗体的免疫组织化学鉴定。在大多数恶性横纹肌瘤肿瘤中,染色体22q11.2处的SMARCB1 / INI1基因由于缺失和/或突变而失活,因此通常可以进行基因诊断。但是,组织可能无法用于遗传分析或没有确定性的研究。我们使用免疫组化方法评估了17种横纹肌瘤和57种中枢神经系统,肾脏或软组织其他肿瘤中SMARCB1 / INI1的表达。总共检查了12例脑,3例肾和2例软组织横纹肌瘤,以及4例胶质母细胞瘤,4例毛细胞星形细胞瘤,4例少突胶质细胞瘤,2例室膜瘤,2脉络丛乳头状瘤,5例垂体腺瘤,4例生殖细胞瘤,4例Xp11.2的肾癌易位,两个透明细胞肉瘤,两个维尔姆氏肿瘤,一个肾髓样癌,两个去增生性小圆形细胞瘤,两个肺泡横纹肌肉瘤,两个胚胎横纹肌肉瘤,一个低度软骨肉瘤,两个骨骼外粘液样软骨肉瘤,一个间充质软骨肉瘤神经鞘瘤,五个转移性癌和四个上皮样肉瘤,两个原发性和两个转移性。通过免疫组织化学分析,所有横纹肌瘤,四个上皮样肉瘤和肾髓样癌的肿瘤细胞均不表达SMARCB1 / INI1。所有其他肿瘤的肿瘤细胞均表达SMARCB1 / INI1。免疫组化评估SMARCB1 / INI1的表达可能有助于诊断中枢神经系统,肾脏和软组织的类横纹肌瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号